Abstract 427P
Background
Nasopharyngeal carcinoma (NPC) is a common and deadly cancer in Indonesia. The objective of this study is to estimate the direct medical hospital costs of NPC using the national health insurance (Jaminan Kesehatan Nasional [JKN]) database in Indonesia.
Methods
The annual costs were estimated using a nationally representative sample of 1% of the JKN population, comprising 2.1 (2019) to 2.4 million (2022) JKN members, from 2019 to 2022.Patients newly diagnosed with NPC, who had at least two NPC-related visits and no prior cancer diagnosis in the year before, were included. Annual costs were calculated over one year (365 days) from the first visit associated with NPC. Costs captured under case-based groups (CBGs) comprised hospitalization and specialist outpatient visits. Non-CBGs costs included radiotherapy, diagnostic procedures, and other costs such as prostheses. Chemotherapy costs were not available for analysis. Costs in Indonesian Rupiah (IDR) were inflated using the Consumer Price Index in 2022 and converted to United States dollars (USD) (1 USD = IDR 15,731).
Results
Of the 590 NPC patients with records in JKN, 262 patients met the inclusion criteria. Around 29% of these patients did not receive any NPC-related treatment one year after diagnosis. The annual mean cost was USD $4,644 per patient. CBGs accounted for 92% of the total mean cost, with inpatient and outpatient CBGs costing USD $2,014 and USD $2,278 per patient, respectively. Non-CBGs cost per patient was USD $353. The total direct medical hospital cost for all NPC patients in the JKN population was extrapolated to be USD $40.5 million per year. This comprised 14% of the JKN cancer expenditure.
Conclusions
NPC imposes a significant economic burden on Indonesia's health system. To contain health expenditures, specific policies are needed to improve cancer prevention and early diagnosis, as well as to efficiently allocate healthcare resources.
Clinical trial identification
Editorial acknowledgement
This study was sponsored by BeiGene, Ltd. Editorial support, under the direction of the authors, was provided by Envision Pharma Inc.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
E. Kristin, S.H. Hutajulu: Financial Interests, Personal, Research Grant, IQVIA funded by BeiGene: IQVIA. Y.A. Dewi: Financial Interests, Personal, Speaker, Consultant, Advisor, Received payment for honoraria from IQVIA, which was contracted by BeiGene to conduct the research (NPC Indonesia). Payment made to my account: IQVIA. S.I. Jaya: Financial Interests, Personal, Research Grant, IQVIA funded by BeiGene: IQVIA. R. Ramadani: Financial Interests, Institutional, Sponsor/Funding, IQVIA funded by BeiGene. Payment made to the institution (IQVIA): IQVIA; Financial Interests, Institutional, Full or part-time Employment, employee of IQVIA, an organization commissioned to conduct research for BeiGene, during the conduct of the study: IQVIA. S.H. Yeo: Financial Interests, Institutional, Sponsor/Funding, IQVIA funded by BeiGene. Payment made to the institution (IQVIA): IQVIA. S. Dhawan, J. Ng: Financial Interests, Institutional, Full or part-time Employment: BeiGene (Beijing) Co., Ltd; Financial Interests, Personal, Stocks/Shares: BeiGene (Beijing) Co., Ltd. All other authors have declared no conflicts of interest.